» Articles » PMID: 15015966

Ability of Myeloma Cells to Secrete Macrophage Inflammatory Protein (MIP)-1alpha and MIP-1beta Correlates with Lytic Bone Lesions in Patients with Multiple Myeloma

Overview
Journal Br J Haematol
Specialty Hematology
Date 2004 Mar 16
PMID 15015966
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Macrophage inflammatory protein (MIP)-1alpha and MIP-1beta have been identified as candidates for multiple myeloma (MM)-derived bone-resorbing factors. To validate the clinical relevance of these observations, we investigated correlations between the ability of MM cells to secrete these chemokines and the extent of MM bone lesions as well as levels of biochemical bone markers in patients with MM. Patients with multiple bone lesions exhibited higher MIP-1alpha and MIP-1beta secretion from MM cells along with elevated urinary deoxypyridinoline (Dpd), without significant elevation of serum bone-specific alkaline phosphatase (BALP) or osteocalcin compared with those with minimal bone lesions. MIP-1alpha and MIP-1beta levels correlated positively with urinary Dpd and serum BALP but not with serum osteocalcin. These results provide further evidence for a causal role of MIP-1alpha and MIP-1beta in the development of lytic bone lesions, and suggest that MM cells suppress osteoblastic bone formation to cause an imbalance of bone turnover and development of destructive bone lesions.

Citing Articles

Different evasion strategies in multiple myeloma.

Wang C, Wang W, Wang M, Deng J, Sun C, Hu Y Front Immunol. 2024; 15:1346211.

PMID: 38464531 PMC: 10920326. DOI: 10.3389/fimmu.2024.1346211.


Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents.

Teramachi J, Miki H, Nakamura S, Hiasa M, Harada T, Abe M J Bone Miner Metab. 2023; 41(3):388-403.

PMID: 36856824 PMC: 9975874. DOI: 10.1007/s00774-023-01403-4.


The CCL5/CCR5 Axis in Cancer Progression.

Aldinucci D, Borghese C, Casagrande N Cancers (Basel). 2020; 12(7).

PMID: 32630699 PMC: 7407580. DOI: 10.3390/cancers12071765.


Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1.

Bosseboeuf A, Mennesson N, Allain-Maillet S, Tallet A, Piver E, Decaux O Cancers (Basel). 2020; 12(5).

PMID: 32429322 PMC: 7281552. DOI: 10.3390/cancers12051254.


Cardiac calcified amorphous tumour associated with multiple myeloma.

Yamanaka T, Fukatsu T, Uchimuro T, Takanashi S BMJ Case Rep. 2020; 13(4).

PMID: 32350053 PMC: 7213708. DOI: 10.1136/bcr-2019-233679.